-
Innovation Ranking
NewInnovation Ranking – AIM ImmunoTech Inc
AIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various...
-
Product Insights
NewNet Present Value Model: AIM ImmunoTech Inc’s Ampligen
Empower your strategies with our Net Present Value Model: AIM ImmunoTech Inc's Ampligen report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
AIMS AA REIT Solar PV Park
AIMS AA REIT Solar PV Park is a solar PV project located in Singapore. The project is being developed by SP Group. The project is at the permitting stage. Empower your strategies with our AIMS AA REIT Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Sector Analysis
NewGhana Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2028
GlobalData expects the construction industry in Ghana to return to growth this year, recording an expansion of 3.2% in real terms in 2024, supported by public and private investment to enhance the transportation network in the country, coupled with the government’s aim to construct 111 hospitals by the end of this year. Growth in 2024 will also be supported by the planned completion of 6,000km of road, 120 bridges and 20 interchanges by the end of the year. In November...
-
Company Insights
NewWorldline – Competitor Profile
Worldline Group is one of the world’s leading payment and transactional service providers, offering end-to-end solutions covering the entire payment value chain. It has omnichannel solutions for merchants, banks, acquirers, payment services providers (PSPs), businesses, and governments. Worldline operates its services in 170 countries, supporting payments in 140 currencies. Worldline operates through three segments—Merchant Services, Financial Services, and Mobility & e-Transactional Services—offering acquiring and processing, card issuing processing, clearing and settlement, open banking, and mobile banking services. Previously, it had...
-
Company Insights
NewHuawei Pay – Competitor Profile
Huawei Pay was launched in 2016 via a collaboration between payment scheme China UnionPay and smartphone brand Huawei, with the aim of competing in China’s exponentially expanding mobile payments market. Huawei Pay offers a ranges of payment services, including in-app and in-store payments. It offers both NFC payment as well as QR code payments for in-store purchases. To ensure privacy and security for payments, Huawei Pay utilizes tokenization and biometric authentication such as fingerprint recognition. Challenging the dominance of established...
-
Product Insights
NewLikelihood of Approval Analysis for Myelofibrosis
Overview How likely is it that the drugs in Myelofibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Myelofibrosis Overview Myelofibrosis is a rare bone marrow disorder where abnormal cells cause...
-
Sector Analysis
NewSix Nations (Rugby Championship), 2024 – Event Analysis
Six Nations Rugby Championship 2024 Event Analysis Report Overview The annual sponsorship revenue for the Six Nations Rugby Championship 2024 is estimated to be $26.33 million. A Six Nations documentary released on Netflix before the tournament was aimed to increase the viewership for this year's tournament. The opening game of the Six Nations brought in an average audience of more than 6 million for host broadcaster France Televisions. The Six Nations Rugby Championship 2024 event analysis report identifies the sponsorship...
-
Thematic Analysis
NewNet Zero Strategies in Aerospace, Defense, and Security – Thematic Intelligence
Net Zero Strategies in Aerospace, Defense, and Security Thematic Overview Net zero means cutting greenhouse gas emissions (GHG) to as close to zero as possible. Any remaining emission is then ‘offset.’ Firms that achieve net zero emissions are called “carbon neutral.” Companies are under pressure to cut emissions as countries aim to achieve their climate commitments. Primarily, they aim to achieve net zero operations by reducing their Scope 1 and 2 emissions and purchasing offsets. Most airline emissions fall under the...
-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Tuberculosis
Overview How likely is it that the drugs in Pulmonary Tuberculosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Tuberculosis Overview Pulmonary tuberculosis (TB) is an infectious respiratory disease caused...